AZN

Prezzo AstraZeneca

Closed
AZN
$204,38
+$2,14(+1,05%)

*Data last updated: 2026-04-15 01:52 (UTC+8)

As of 2026-04-15 01:52, AstraZeneca (AZN) is priced at $204,38, with a total market cap of $316,84B, a P/E ratio of 13,26, and a dividend yield of 1,58%. Today, the stock price fluctuated between $202,13 and $204,69. The current price is 1,11% above the day's low and 0,15% below the day's high, with a trading volume of 2,20M. Over the past 52 weeks, AZN has traded between $66,16 to $212,72, and the current price is -3,92% away from the 52-week high.

AZN Key Stats

Yesterday's Close$202,24
Market Cap$316,84B
Volume2,20M
P/E Ratio13,26
Dividend Yield (TTM)1,58%
Dividend Amount$2,14
Diluted EPS (TTM)6,68
Net Income (FY)$10,25B
Revenue (FY)$58,73B
Earnings Date2026-05-05
EPS Estimate2,53
Revenue Estimate$14,86B
Shares Outstanding1,56B
Beta (1Y)0.275
Ex-Dividend Date2026-02-20
Dividend Payment Date2026-03-23

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOPascal Claude Roland Soriot
HeadquartersCambridge,None,GB
Employees (FY)2,02K
Average Revenue (1Y)$29,03M
Net Income per Employee$5,06M

AstraZeneca (AZN) FAQ

What's the stock price of AstraZeneca (AZN) today?

x
AstraZeneca (AZN) is currently trading at $204,38, with a 24h change of +1,05%. The 52-week trading range is $66,16–$212,72.

What are the 52-week high and low prices for AstraZeneca (AZN)?

x

What is the price-to-earnings (P/E) ratio of AstraZeneca (AZN)? What does it indicate?

x

What is the market cap of AstraZeneca (AZN)?

x

What is the most recent quarterly earnings per share (EPS) for AstraZeneca (AZN)?

x

Should you buy or sell AstraZeneca (AZN) now?

x

What factors can affect the stock price of AstraZeneca (AZN)?

x

How to buy AstraZeneca (AZN) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

AstraZeneca (AZN) Latest News

2025-03-20 09:53

Exclusive Offer for Gate.io - Claim Your Share of Million Dollar Trading Benefits!

P2P Event Overview The exclusive trading event for Gate.io CIS users has started. During the event, both new and existing users can complete deposit and trading tasks to earn up to 30 USDT rewards. **Event Dates : March 17, 2025 - April 25, 2025** **Eligible Currencies** : RUB, UAH, KZT, UZS, BYN, AZN, AMD **Event 1: New User Registration Bonus ** During the event, new users who register, complete KYC verification, and meet the following tasks can receive corresponding rewards: * Deposit ≥ 30 USDT: Get a 2 USDT Futures Bonus * Deposit ≥ 100 USDT: Get an 8 USDT Futures Bonus * Deposit ≥ 300 USDT: Get a 25 USDT Futures Bonus **Event 2: Existing User Trading Contest ** During the event, deposit and complete at least one trade to receive corresponding trading fee rebate vouchers: * Deposit ≥ 200 USDT: Get a 3 USDT trading fee rebate voucher * Deposit ≥ 500 USDT: Get a 10 USDT trading fee rebate voucher * Deposit ≥ 1000 USDT: Get a 30 USDT trading fee rebate voucher <div style="text-align: center;"><a data-type="gate-activity" rel="" href="https://www.gate.io/campaigns/617" target="_blank" style="text-decoration: none !important;display: inline-block;"><div class="gateactivity-btn-style" style="width: 240px;height: 40px;box-sizing: border-box;padding: unset;border-radius: 99px;display: inline-flex;align-items: center;justify-content: center;background: #3377FF;cursor: pointer;"><strong><span style="color:#fff; text-decoration: none;">Sign up now</span></strong></div></a></div> **Terms and Conditions** : * This event is available to users in CIS regions, including **RUB, UAH, KZT, UZS, BYN, AZN, AMD.** * Users must **click there to register for the event** to be eligible for rewards. * Trading fee rebate vouchers must be manually activated and can only be activated one at a time. Vouchers expire after the designated time, and after expiration, any remaining balance of the voucher will become void. <a href="https://www.gate.io/help/guide/reward_center/38086/trading-fee-rebate-voucher-introduction" target="_blank">Learn more about Trading Fee Rebate Voucher.</a> * Futures bonuses should be claimed and used for trading within the validity period, and will become invalid after the expiration date. Learn more about <a href="https://www.gate.io/help/futures/bonusvoucher/39028/futures-bonus" target="_blank">Futures Bonus </a>. * Futures trading carries risks; Gate.io is not responsible for any losses incurred using trading fee rebate voucher or engaging in futures trading. * As per our our Users Agreement, this service is unavailable to users in the UK and other restricted locations. * Users who fail to meet the requirements may forfeit their eligibility for rewards. All users must strictly comply with Gate Users Agreement. * Gate.io reserves the right to disqualify any participants engaged in dishonest or abusive activities during the event, including bulk account registrations to obtain additional bonuses and any other activities related to illegal, fraudulent, or harmful purposes. * Gate.io reserves the right to modify the terms of this event without prior notice to users. If you have any questions, please contact your P2P manager via @Gatep2p_bot. Join our Telegram channel: https://t.me/P2P_GateCommunity<sp> **Gateway to Crypto** Trade over 3,700 cryptocurrencies safely, quickly, and easily on Gate.io • Visit our <a href="https://www.gate.io/" target="_blank">Official Website</a> • Download <a href="https://www.gate.io/mobileapp" target="_blank">Gate.io App</a> / <a href="https://www.gate.io/mobileapp" target="_blank">Web</a> now • Follow us on Gate.io <a href="https://x.com/gate_io" rel="nofollow noopener noreferrer" target="_blank">X (Twitter)</a> to get more bonuses • Join our <a href="https://t.me/gateio_en" rel="nofollow noopener noreferrer" target="_blank">Telegram</a> to discuss hot topics • Join our <a href="https://www.gate.io/community" target="_blank">Global Community</a> to get more updates • We provide <a href="https://www.gate.io/proof-of-reserves" target="_blank">100% proof of reserves</a> • <a href="https://www.gate.io/signup" target="_blank">Sign up</a> to enjoy max. $10,000 in rewards exclusively for new users • Get 40% commission from <a href="https://www.gate.io/referral" target="_blank">referrals</a> Gate.io Team March 17, 2025</sp>

Hot Posts su AstraZeneca (AZN)

SelfRugger

SelfRugger

04-11 05:01
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Strong Multi‑Year Share Gains? ===================================================================================== Simply Wall St Tue, February 17, 2026 at 3:11 PM GMT+9 6 min read In this article: AZN +0.50% Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. * If you are wondering whether AstraZeneca's share price still offers value or is starting to look expensive, the next sections will walk through what the current market price might be implying. * AstraZeneca's shares last closed at £151.60, with returns of 9.2% over 7 days, 7.9% over 30 days, 11.5% year to date, 32.2% over 1 year, 40.0% over 3 years and 136.3% over 5 years. This gives helpful context before looking at valuation. * Recent news coverage has largely focused on AstraZeneca's position as a major pharmaceuticals group and ongoing interest in its wider pipeline and portfolio. This helps explain why many investors keep a close eye on the share price. Commentators often point to how sentiment around large healthcare companies can shift quickly as trial data, regulatory decisions or product updates emerge. * On Simply Wall St's 6 point valuation checklist, AstraZeneca currently scores 3 out of 6. We will next look at what different valuation methods say about that score, before finishing with a broader way to think about what the market is really pricing in. AstraZeneca delivered 32.2% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. ### Approach 1: AstraZeneca Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and discounting them back to a present value. For AstraZeneca, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model, based on cash flows reported in US$. The latest twelve month free cash flow is about US$9.5b. Analyst projections and subsequent extrapolations suggest free cash flow of around US$20.2b in 2030, with interim annual figures between 2026 and 2035 ranging from roughly US$10.9b to US$27.1b before discounting. After discounting these projected cash flows, the model arrives at an estimated intrinsic value of US$228.28 per share. Compared with the current share price of £151.60, this implies AstraZeneca is trading at a 33.6% discount to that DCF estimate, which indicates that the shares may be undervalued on this measure. **Result: UNDERVALUED** Our Discounted Cash Flow (DCF) analysis suggests AstraZeneca is undervalued by 33.6%. Track this in your watchlist or portfolio, or discover 8 more high quality undervalued stocks. AZN Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for AstraZeneca. ### Approach 2: AstraZeneca Price vs Earnings (P/E) For a profitable company like AstraZeneca, the P/E ratio is a useful yardstick because it links what you pay for the shares to the earnings the business is already generating. Story continues In simple terms, higher expected growth and lower perceived risk usually justify a higher, or more generous, P/E multiple, while lower growth expectations or higher risk tend to line up with a lower, or more cautious, P/E. AstraZeneca currently trades on a P/E of 31.34x. That is above the Pharmaceuticals industry average of 21.97x and also above the broader peer group average of 14.31x, which indicates the market is already attaching a premium to its earnings. Simply Wall St’s Fair Ratio metric estimates what a more tailored P/E might look like, given AstraZeneca’s earnings growth profile, profit margins, industry, market cap and risk factors. This tends to be a more specific guide than a simple comparison with peers or the sector, because it adjusts for company level characteristics rather than assuming all firms should trade on the same multiple. Here, the Fair Ratio for AstraZeneca is 33.13x, which is slightly above the current 31.34x. On this basis, the shares appear somewhat cheap relative to that Fair Ratio estimate. **Result: UNDERVALUED** LSE:AZN P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 4 top founder-led companies. ### Upgrade Your Decision Making: Choose your AstraZeneca Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives, which let you set out your own story for AstraZeneca, link that story to specific assumptions about future revenue, earnings and margins, and then see the Fair Value that results from those numbers. This is all available within an easy tool on the Community page that updates as new news or earnings arrive and lets you compare different views. For example, you can look at a higher Fair Value of about £182.81 that reflects a more optimistic view on oncology and 2030 sales ambitions, or a lower Fair Value of about £108.53 that reflects more caution on drug pricing, patent expiries and execution risk, and then decide for yourself how those Fair Values stack up against the current share price. For AstraZeneca, however, we will make it really easy for you with previews of two leading AstraZeneca Narratives: First up is a more optimistic take that leans into the strength of the pipeline and long term earnings power. **🐂 AstraZeneca Bull Case** Fair value: £152.79 Implied discount to this fair value: 0.8% relative to the last close of £151.60 Revenue growth assumption: 5.77% a year * Analysts in this camp see a strong late stage pipeline in oncology, rare diseases and cardiovascular or metabolic therapies, with management pointing to more than US$10b of potential peak risk adjusted revenue from new medicines. * They factor in ongoing expansion in emerging markets such as China, Latin America and Southeast Asia, together with investments in technologies like ADCs, bispecific antibodies and mRNA platforms, which are expected to support higher margins and earnings resilience. * Key risks they highlight include exposure to price controls, biosimilar competition and heavy dependence on a handful of blockbuster drugs, plus the chance that high R&D spend does not consistently translate into productive launches. Now compare that with a more cautious view that leans harder on drug pricing pressure and patent expiries. **🐻 AstraZeneca Bear Case** Fair value: £108.53 Implied premium to this fair value: 39.7% relative to the last close of £151.60 Revenue growth assumption: 3.50% a year * This narrative focuses on tighter global controls on drug pricing and reimbursement, with concerns that this could cap revenue growth and squeeze margins as more of AstraZeneca's portfolio targets chronic conditions. * It puts more weight on upcoming patent expiries for drugs like Tagrisso, Farxiga and Imfinzi, with the view that biosimilar and generic competition could erode high margin revenue streams and lower returns later on. * It also flags execution and geopolitical risk, pointing to heavy ongoing R&D and manufacturing investment, expansion into higher risk markets and the potential impact of policy shifts, tariffs or supply chain disruption on long term earnings and cash flow stability. Taken together, these two narratives show you how different assumptions about pricing, patents, growth and execution can lead to very different views on fair value, even when they start from the same set of public information. Do you think there's more to the story for AstraZeneca? Head over to our Community to see what others are saying! LSE:AZN 1-Year Stock Price Chart _ This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ _Companies discussed in this article include AZN.L._ **Have feedback on this article? Concerned about the content? Get in touch with us directly.**_ Alternatively, email editorial-team@simplywallst.com_ Terms and Privacy Policy Privacy Dashboard More Info
1
0
0
0